Solfrid Hegstad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Solfrid Hegstad has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
A. S. Christophersen
Norwegian Institute of Public Health, Division of Forensic Toxicology and Drug Abuse , P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway
2 shared publications- Elisabeth Leere Øiestad
University of Oslo
2 shared publications H. Z. Khiabani
Norwegian Institute of Public Health, Division of Forensic Toxicology and Drug Abuse , P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway
2 shared publicationsA.S. Christophersen
Norwegian Institute of Public Health, Division of Forensic Toxicology and Drug Abuse , P.O. Box 4404 Nydalen, NO-0403 Oslo
1 shared publicationAsbjørg S Christophersen
1 shared publication- Hassan Z. Khiabani
Divisjon for rettstoksikologi og rusmiddelforskning, Nasjonalt folkehelseinstitutt, Postboks 4404 Nydalen, 0403 Oslo
1 shared publication
Latest Publications
- Open Access
- 1 June 2008
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 32 (5) , 364-372
Drug Screening of Hair by Liquid Chromatography-Tandem Mass Spectrometry
Hair has become an important matrix for drug analysis, complementary to blood and urine as a matrix. A prolonged detection window makes hair analysis suitable for lhe detection of exposure to illegal and medicinal drugs for periods up to 12 months. In the present study, a liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for drug screening in hair was developed and validated. To 20 mg of hair, 0.45 mL of acetonitrile/25 mM formic acid (5:95 v/v) and 50 µL of deuterated internal standards were added, and the sample was incubated in a water bath at 37°C for 18 h. LC separation was achieved with a Zorbax SB-Phenyl column (2.1 × 100 mm, 3.5-µm particle). Mass detection was performed by positive ion mode electrospray LC-MS-MS and included the following drugs/metabolites: nicotine, cotinine, morphine, 6-monoacetylmorphine, codeine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine, cocaine, benzoylecgonine, 7-aminonitrazepam, 7-aminoclonazepam, 7-aminoflunitrazepam, oxazepam, diazepam, alprazolam, zopiclone, zolpidem, carisoprodol, meprobamate, buprenorphine, and methadone. Within- and between-assay relative standard deviations varied from 2.0% to 12% and 2.7% to 15%, respectively. The accuracies were in the range of −24% to 16%, and recoveries ranged from 25% to 100%. The LC-MS-MS method proved to be simple and robust for the determination of drugs in hair. It has been used for authentic samples in our laboratory in the past year.
- 1 June 2008
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 32 (5) , 364-372
Open AccessDrug Screening of Hair by Liquid Chromatography-Tandem Mass Spectrometry
Hair has become an important matrix for drug analysis, complementary to blood and urine as a matrix. A prolonged detection window makes hair analysis suitable for lhe detection of exposure to illegal and medicinal drugs for periods up to 12 months. In the present study, a liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for drug screening in hair was developed and validated. To 20 mg of hair, 0.45 mL of acetonitrile/25 mM formic acid (5:95 v/v) and 50 µL of deuterated internal standards were added, and the sample was incubated in a water bath at 37°C for 18 h. LC separation was achieved with a Zorbax SB-Phenyl column (2.1 × 100 mm, 3.5-µm particle). Mass detection was performed by positive ion mode electrospray LC-MS-MS and included the following drugs/metabolites: nicotine, cotinine, morphine, 6-monoacetylmorphine, codeine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine, cocaine, benzoylecgonine, 7-aminonitrazepam, 7-aminoclonazepam, 7-aminoflunitrazepam, oxazepam, diazepam, alprazolam, zopiclone, zolpidem, carisoprodol, meprobamate, buprenorphine, and methadone. Within- and between-assay relative standard deviations varied from 2.0% to 12% and 2.7% to 15%, respectively. The accuracies were in the range of −24% to 16%, and recoveries ranged from 25% to 100%. The LC-MS-MS method proved to be simple and robust for the determination of drugs in hair. It has been used for authentic samples in our laboratory in the past year.
- 17 January 2008
- Vol. 128 (2) , 184-5
[Determination of buprenorphine in urine].
Buprenorphine is one of the drugs used for treatment of opioid-dependent patients enrolled in rehabilitation programs in Norway. Buprenorphine is metabolized in the liver by cytochrome P450 to the active metabolite norbuprenorphine, and further to buprenorphine-glucuronide and norbuprenorphine-glucuronide. The Division of Forensic Toxicology and Drug Abuse at the Norwegian Institute of Public Health has during the past 5 years received an increasing number of urine samples for buprenorphine analysis. All urine samples with question of buprenorphine have since August 2005 been analysed with a new method, which analyses the glucuronides of buprenorphine and norbuprenorphine in urine. This method is fast and simple and saves time and resources in our routine laboratory.
- 17 January 2008
- Vol. 128 (2) , 184-5
[Determination of buprenorphine in urine].
Buprenorphine is one of the drugs used for treatment of opioid-dependent patients enrolled in rehabilitation programs in Norway. Buprenorphine is metabolized in the liver by cytochrome P450 to the active metabolite norbuprenorphine, and further to buprenorphine-glucuronide and norbuprenorphine-glucuronide. The Division of Forensic Toxicology and Drug Abuse at the Norwegian Institute of Public Health has during the past 5 years received an increasing number of urine samples for buprenorphine analysis. All urine samples with question of buprenorphine have since August 2005 been analysed with a new method, which analyses the glucuronides of buprenorphine and norbuprenorphine in urine. This method is fast and simple and saves time and resources in our routine laboratory.
- Open Access
- 1 May 2007
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 31 (4) , 214-219
Rapid Quantification of Buprenorphine-Glucuronide and Norbuprenorphine-Glucuronide in Human Urine by LC-MS-MS
A liquid chromatography-tandem mass spectrometry (LC-MS-MS) method was developed and validated for the determination of buprenorphine-glucuronide (BUP-G) and norbuprenorphineglucuronide (NBUP-G) in human urine. The method included a dilution step followed by filtration through a Mini-Uniprep Filter and direct injection onto the LC column. The analytes were quantified in multiple reactions monitoring mode using one transition ion. Norbuprenorpine-d3 (NBUP-d3) was used as the internal standard. The concentration ranges were 6–161 ng/mL for BUP-G and 12–295 ng/mL for NBUP-G. Recoveries determined after filtration for the analytes were 75%. The between-day precision of the method was in the range of 4.8–11%. The limits of quantification were found to be 4.6 ng/mL for BUP-G and 11.8 ng/mL for NBUP-G. Approximately 1000 samples from law enforcement, prison inmates, probation services, and hospitals were analyzed by the presented method. The ratios of drug glucuronides versus creatinine were calculated for a selection of samples (n = 151), where there was information on treatment with buprenorphine between 16 and 20 rag/day. The majority (86%) of the samples had a ratio of BUP-G/creatinine below 570 µg/g, and 76% of the samples had NBUP-G/creatinine lower than 1060 µg/g. The LC-MS-MS method proved to be robust and specific for the determination of BUP-G and NBUP-G in urine.
- 1 May 2007
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 31 (4) , 214-219
Open AccessRapid Quantification of Buprenorphine-Glucuronide and Norbuprenorphine-Glucuronide in Human Urine by LC-MS-MS
A liquid chromatography-tandem mass spectrometry (LC-MS-MS) method was developed and validated for the determination of buprenorphine-glucuronide (BUP-G) and norbuprenorphineglucuronide (NBUP-G) in human urine. The method included a dilution step followed by filtration through a Mini-Uniprep Filter and direct injection onto the LC column. The analytes were quantified in multiple reactions monitoring mode using one transition ion. Norbuprenorpine-d3 (NBUP-d3) was used as the internal standard. The concentration ranges were 6–161 ng/mL for BUP-G and 12–295 ng/mL for NBUP-G. Recoveries determined after filtration for the analytes were 75%. The between-day precision of the method was in the range of 4.8–11%. The limits of quantification were found to be 4.6 ng/mL for BUP-G and 11.8 ng/mL for NBUP-G. Approximately 1000 samples from law enforcement, prison inmates, probation services, and hospitals were analyzed by the presented method. The ratios of drug glucuronides versus creatinine were calculated for a selection of samples (n = 151), where there was information on treatment with buprenorphine between 16 and 20 rag/day. The majority (86%) of the samples had a ratio of BUP-G/creatinine below 570 µg/g, and 76% of the samples had NBUP-G/creatinine lower than 1060 µg/g. The LC-MS-MS method proved to be robust and specific for the determination of BUP-G and NBUP-G in urine.
- Open Access
- 1 January 2006
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 30 (1) , 31-37
Determination of Benzodiazepines in Human Urine using Solid-Phase Extraction and High-Performance Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry
A liquid chromatography-tandem mass spectrometry (LC-MS-MS) method has been developed and validated for the determination of benzodiazepines, on the market in Norway, and/or their metabolites in human urine. The following compounds were included: 7-aminonitrazepam, 7-aminoclonazepam, 7-aminoflunitrazepam, alprazolam, α-hydroxyalprazolam, oxazepam, 3-OH-diazepam, and n-desmethyldiazepam. The method includes hydrolysis of urine samples (0.5 mL) with β-glucuronidase at 60°C for 2 h before solid-phase extraction with a polymer-based mixed.mode column. The analytes were quantified in multiple reaction monitoring mode using two transitions. Deuterated analogues were used as internal standards for all analytes except 7-aminonitrazepam and α-hydroxyalprazolam, which were quantified using 7-aminoclonazepam-d4 and alprazolam-d5, respectively. The concentration range was 0.1–8.0µM for 7-aminonitrazepam, 7-aminoclonazepam, 7-aminoflunitrazepam, alprazolam, and α-hydroxyalprazolam and 0.5–40µM for the other compounds. The average recovery for the different analytes ranged from 56% to 83%. The between-day precision of the method was in the range of 3–12%. The limits of quantification were found to be between 0.002 and 0.01µM for the different compounds. Comparison with other analytical methods was performed for method validation, using approximately 500 samples provided by the routine laboratory at the Norwegian Institute of Public Health. The LC-MS-MS method has proven to be robust and specific for the determination of benzodiazepines in urine. It has been routinely used for approximately 1800 samples in the past 7 months.
- 1 January 2006
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 30 (1) , 31-37
Open AccessDetermination of Benzodiazepines in Human Urine using Solid-Phase Extraction and High-Performance Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry
A liquid chromatography-tandem mass spectrometry (LC-MS-MS) method has been developed and validated for the determination of benzodiazepines, on the market in Norway, and/or their metabolites in human urine. The following compounds were included: 7-aminonitrazepam, 7-aminoclonazepam, 7-aminoflunitrazepam, alprazolam, α-hydroxyalprazolam, oxazepam, 3-OH-diazepam, and n-desmethyldiazepam. The method includes hydrolysis of urine samples (0.5 mL) with β-glucuronidase at 60°C for 2 h before solid-phase extraction with a polymer-based mixed.mode column. The analytes were quantified in multiple reaction monitoring mode using two transitions. Deuterated analogues were used as internal standards for all analytes except 7-aminonitrazepam and α-hydroxyalprazolam, which were quantified using 7-aminoclonazepam-d4 and alprazolam-d5, respectively. The concentration range was 0.1–8.0µM for 7-aminonitrazepam, 7-aminoclonazepam, 7-aminoflunitrazepam, alprazolam, and α-hydroxyalprazolam and 0.5–40µM for the other compounds. The average recovery for the different analytes ranged from 56% to 83%. The between-day precision of the method was in the range of 3–12%. The limits of quantification were found to be between 0.002 and 0.01µM for the different compounds. Comparison with other analytical methods was performed for method validation, using approximately 500 samples provided by the routine laboratory at the Norwegian Institute of Public Health. The LC-MS-MS method has proven to be robust and specific for the determination of benzodiazepines in urine. It has been routinely used for approximately 1800 samples in the past 7 months.